3 VAN DE GRAAFF DRIVE, BURLINGTON, MA
Call Notice for All Tranche A Common Stock Purchase Warrants
Reports Positive 6-Month REVEAL-1 Open-Label Results Showing Sustained Post-GLP-1 Weight Maintenance After a Single Revita® Procedure
Reports Third Quarter 2025 Results; Revita® Clinical Momentum Builds Toward 2026 Pivotal Readout and PMA Filing, Cash Runway Extended into Early 2027
Shareholder votes
Announces Pricing of $60 Million Underwritten Offering of Common Stock
REMAIN-1 Study Shows Revita® Aids Weight Maintenance Post-GLP-1
Changes in Board, Management or Compensation
Announces Second Quarter 2025 Financial Results and Business Updates
Q3
Q2
Q1
FY 2024
FY 2023
Prospectus filed pursuant to Rule 424(b)(5)
Effectiveness Notice
Amended Registration Statement for Securities Offered under a Shelf Registration
Registration Statement for Securities Offered under a Shelf Registration
Registration Statement for Securities to be Offered to Employees
Prospectus filed pursuant to Rule 424(b)(4)
Definitive Proxy Statement
PRE 14A
Additional Proxy Materials
Statement of Changes in Beneficial Ownership
Schedule 13G - Ownership Report
Amended Schedule 13G - Ownership Report
SEC Staff Correspondence
Correspondence